W. Zhang

LLM-assisted evidence audit of late-stage cancer incidence as a screening trial endpoint

Background Late-stage cancer incidence is being considered as an earlier endpoint in cancer-screening trials, but its trial-level association with cancer-specific mortality may depend on evidence selection and endpoint harmonization. We evaluated the robustness of this association to source-verified additions. Methods...